Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Recipient : Ikarovec
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 01, 2023
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Recipient : Ikarovec
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Agreement
Details : Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
Brand Name : BNT162
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : BNT162
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
